Table 2.
Comparative Analysis of Prognostic Ophthalmic Markers of Diabetic Retinopathy
| Before Injection | After 6 IVR Doses | P value | |
|---|---|---|---|
| BCVA (ETDRS letters) | 67.60 ± 3.29 | 76.36 ± 1.61 | <0.0001* |
| CRT (µm) | 479.12 ± 16.66 | 369.12 ± 13.02 | <0.0001* |
| Total number of MAs | 5.68 ± 3.41 | 1.60 ± 1.73 | <0.0001* |
| MA formation rate (MA number/month) |
2.48 ± 1.98 | 0.96 ± 1.02 | <0.0001* |
| MA disappearance rate (MA number/month) |
4.40 ± 2.66 | 0.96 ± 1.09 | <0.0001* |
| MA turnover | 6.88 ± 3.83 | 1.92 ± 1.75 | <0.0001* |
| Perifoveal non-perfused area (mm2) | 2.517 ± 0.456 | 2.495 ± 0.293 | 0.221 |
Notes: MA formation rate, MA disappearance rate, MA turnover are defined as before injection and after first injection. The values are presented as mean±SD and range unless otherwise indicated. Statistically significance is p < 0.05 with *Repeated measures analysis of variance.
Abbreviations: IVR, intravitreal ranibizumab; BCVA, best-corrected visual acuity; CRT, central retinal thickness; MA, microaneurysm; ETDRS, Early Treatment Diabetic Retinopathy Study.